hVIVO（OPOR.F）株式概要hVIVO plcは英国、欧州、北米で医薬品サービスおよび開発業務受託会社として事業を展開している。 詳細OPOR.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金2/6報酬株価収益率（ 8.1 x） US市場（ 18.6 x）を下回っています。リスク分析今後3年間の収益は年平均43%減少すると予測されている。 株式の流動性は非常に低い 高いレベルの非現金収入 利益率(9.7%)は昨年より低い(26%) +1 さらなるリスクすべてのリスクチェックを見るOPOR.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.08645.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m67m2016201920222025202620282031Revenue UK£59.8mEarnings UK£5.8mAdvancedSet Fair ValueView all narrativeshVIVO plc 競合他社Mesa LaboratoriesSymbol: NasdaqGS:MLABMarket cap: US$600.2mSotera HealthSymbol: NasdaqGS:SHCMarket cap: US$4.5bStevanato GroupSymbol: NYSE:STVNMarket cap: US$4.9bbioteSymbol: NasdaqGM:BTMDMarket cap: US$70.8m価格と性能株価の高値、安値、推移の概要hVIVO過去の株価現在の株価UK£0.08652週高値UK£0.08652週安値UK£0.086ベータ1.61ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化-81.28%IPOからの変化4,363.45%最新ニュースお知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdomお知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.最新情報をもっと見るRecent updatesお知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdomお知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.お知らせ • Jul 18hVIVO plc Announces Resignation of Tracey James as Non-Executive Director, Effective 18 July 2025hVIVO plc announced that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect (18 July 2025). The Company confirmed that Ms. James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director, and the Company will announce the results of this process in due course. Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, with a further announcement to be made in due course.お知らせ • May 13hVIVO plc, Annual General Meeting, Jun 05, 2025hVIVO plc, Annual General Meeting, Jun 05, 2025. Location: the offices of cavendish capital markets ltd, 1 bartholomew close, ec1a 7bl, london United Kingdomお知らせ • Apr 10+ 1 more updatehVIVO plc Proposes Ordinary Dividend for the Year Ended 31 December 2024, Payable 11 June 2025hVIVO plc announced A final dividend for the year ended 31 December 2024 of £1,374,000 (0.20p per ordinary share) is recommended by the Directors and is to be paid to all ordinary shareholders on the register at the close of business on 16 May 2025 with payment being made on 11 June 2025, subject to shareholder approval at the Annual General Meeting. The corresponding ex-dividend date is 15 May 2025.お知らせ • Mar 21hVIVO plc to Report Fiscal Year 2024 Results on Apr 10, 2025hVIVO plc announced that they will report fiscal year 2024 results at 11:00 AM, GMT Standard Time on Apr 10, 2025お知らせ • Feb 27hVIVO plc (AIM:HVO) acquired Cryo Store Limited.hVIVO plc (AIM:HVO) acquired Cryo Store Limited on February 27, 2025. Under the terms of the Acquisition, three managers of Cryostore will be issued up to 2,773,982 ordinary shares of £1p each in hVIVO ('Consideration Shares') with an aggregate value of up to £0.5 million at the average closing share price for the ten days prior to 24 February 2024. 1,386,991of the Consideration Shares (being 50%) will be allotted on the 12-month anniversary of completion with1,386,991 of the Consideration Shares (being 50%) being allotted on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group at the time of the allotments. For the period ending December 31, 2024, Cryo Store Limited reported total revenue of £0.89 million and EBITDA of £0.52 million. As of December 31, 2024, Cryo Store Limited reported total common equity of £0.84 million. Geoff Nash, Camilla Hume, Harriet Ward, Nigel Birks, Louise Talbot of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Cryo Store Limited on February 27, 2025.お知らせ • Jan 31hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million.hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million on January 29, 2025. Under the terms of agreement, the Acquisition has been completed for a cash consideration of €10.0 million, wholly funded from the Group's existing cash resources. For the period ending December 31, 2024, The Mannheim and Kiel units recorded unaudited revenues of €19.9 million, with an adjusted EBITDA loss of €1.8 million. Under hVIVO's ownership the two units will undergo an investment and restructuring programme to assist with their integration which is expected to cost c.€2.5 million in 2025 including net liabilities being acquired of less than €0.5 million. Following the Acquisition, average contract sizes across the Group are anticipated to increase, as well as growth in the CRS sales pipeline. The current senior leadership team at CRS, consisting of Dr. Elisabeth Lackner, Chief Executive Officer; Catherine Canales, Chief Commercial Officer; Prof. Dr. Thomas Forst, Chief Medical Officer; and Till Mieskes, Chief Financial Officer, will continue in their roles. The Acquisition expected to be earnings accretive in 2026. The integration of the Acquisition into the wider Group is expected to impact EBITDA margins in the short term and the Group expects to deliver strong revenue growth in 2026 and a significant improvement on EBITDA margins following the integration of CRS. Geoff Nash and Camilla Hume of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Two Clinical Research Units of Crs Clinical Research Services Management GmbH on January 29, 2025.お知らせ • Aug 20hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024hVIVO plc announced that they will report first half, 2024 results on Sep 10, 2024お知らせ • Aug 05hVIVO Proposes Cancellation of Admission to Trading on Euronext GrowthhVIVO plc announced its intention to cancel its admission ("the Cancellation") to trading on Euronext Growth. As hVIVO's primary operations, along with the majority of its employees and investor base, are in the UK,the Board has decided to consolidate trading of the Company's stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO's Ordinary Shares which will continue to trade on AIM under the ticker "HVO". In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024.お知らせ • Apr 16hVIVO plc, Annual General Meeting, May 13, 2024hVIVO plc, Annual General Meeting, May 13, 2024, at 10:00 Coordinated Universal Time.お知らせ • Mar 27hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024hVIVO plc announced that they will report fiscal year 2023 results on Apr 09, 2024お知らせ • Feb 15hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,955,178 Price\Range: £0.28 Transaction Features: Subsequent Direct Listingお知らせ • Jan 02hVIVO plc Signs £6.3 Million Human Challenge Study ModelhVIVO plc announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers. The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset. Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD. To date, no antiviral has been approved in the prevention or treatment of HRV infection.お知らせ • Sep 12hVIVO plc Increases Revenue Guidance for 2023The Board of hVIVO plc has increased its revenue guidance to £55 million for 2023.お知らせ • Aug 24hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023hVIVO plc announced that they will report first half, 2023 results on Sep 12, 2023お知らせ • Jun 30hVIVO plc to Develop Human Metapneumovirus Challenge ModelhVIVO plc is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in first half 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from second half of 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide. Up to 16% of the children infected with hMPV develop more severe symptoms2, with over 16,000 deaths worldwide in children under the age of five each year. Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.お知らせ • Jan 25hVIVO plc Provides Earnings Guidance for the Full Year 2022hVIVO plc provided earnings guidance for the full year 2022. The group expected to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.株主還元OPOR.FUS Life SciencesUS 市場7D0%4.1%1.1%1Yn/a8.3%28.7%株主還元を見る業界別リターン: OPOR.FがUS Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: OPOR.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is OPOR.F's price volatile compared to industry and market?OPOR.F volatilityOPOR.F Average Weekly Movementn/aLife Sciences Industry Average Movement8.0%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: OPOR.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のOPOR.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a301Mo Khanwww.hvivo.comhVIVO plcは、英国、欧州、北米で医薬品サービスおよび開発業務受託会社として事業を展開している。同社は、ヒトチャレンジ臨床試験を用いたワクチンや抗ウイルスのテストに携わり、アッセイ開発、細胞ベースアッセイ、分子学、免疫学、ウイルス学、臨床フィールドトレイルロジスティクス、バイオマーカー分析サービスなどのラボサービスを提供している。RSV、インフルエンザ、COVID-19、hMPV、HRV、喘息、マラリア、COPDなどの疾患に対するヒトチャレンジ試験モデルのポートフォリオを有している。加えて、同社はウイルス学と免疫学に特化した研究所を提供しており、前臨床および臨床の呼吸器疾患治療薬、ワクチンの発見と開発をサポートする一連のサービスを提供している。さらに、前臨床および初期臨床研究サービス、営業・マーケティングサービス、データ管理、統計サービス、医薬品開発コンサルタント・サービスも提供している。同社は大手製薬会社やバイオテクノロジー企業にサービスを提供している。hVIVO plcの本社は英国ロンドンにある。もっと見るhVIVO plc 基礎のまとめhVIVO の収益と売上を時価総額と比較するとどうか。OPOR.F 基礎統計学時価総額US$56.76m収益（TTM）US$7.00m売上高(TTM)US$72.13m8.1xPER（株価収益率0.8xP/SレシオOPOR.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OPOR.F 損益計算書（TTM）収益UK£54.47m売上原価UK£43.77m売上総利益UK£10.70mその他の費用UK£5.42m収益UK£5.28m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.0078グロス・マージン19.64%純利益率9.70%有利子負債／自己資本比率0%OPOR.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.2%現在の配当利回り26%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/01 02:36終値2026/01/02 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋hVIVO plc 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Michael MitchellCavendishEdward ThomasonCGS InternationalColin GrantDavy7 その他のアナリストを表示
お知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdom
お知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026
お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.
お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.
お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025
お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.
お知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdom
お知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026
お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.
お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.
お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025
お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.
お知らせ • Jul 18hVIVO plc Announces Resignation of Tracey James as Non-Executive Director, Effective 18 July 2025hVIVO plc announced that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect (18 July 2025). The Company confirmed that Ms. James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director, and the Company will announce the results of this process in due course. Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, with a further announcement to be made in due course.
お知らせ • May 13hVIVO plc, Annual General Meeting, Jun 05, 2025hVIVO plc, Annual General Meeting, Jun 05, 2025. Location: the offices of cavendish capital markets ltd, 1 bartholomew close, ec1a 7bl, london United Kingdom
お知らせ • Apr 10+ 1 more updatehVIVO plc Proposes Ordinary Dividend for the Year Ended 31 December 2024, Payable 11 June 2025hVIVO plc announced A final dividend for the year ended 31 December 2024 of £1,374,000 (0.20p per ordinary share) is recommended by the Directors and is to be paid to all ordinary shareholders on the register at the close of business on 16 May 2025 with payment being made on 11 June 2025, subject to shareholder approval at the Annual General Meeting. The corresponding ex-dividend date is 15 May 2025.
お知らせ • Mar 21hVIVO plc to Report Fiscal Year 2024 Results on Apr 10, 2025hVIVO plc announced that they will report fiscal year 2024 results at 11:00 AM, GMT Standard Time on Apr 10, 2025
お知らせ • Feb 27hVIVO plc (AIM:HVO) acquired Cryo Store Limited.hVIVO plc (AIM:HVO) acquired Cryo Store Limited on February 27, 2025. Under the terms of the Acquisition, three managers of Cryostore will be issued up to 2,773,982 ordinary shares of £1p each in hVIVO ('Consideration Shares') with an aggregate value of up to £0.5 million at the average closing share price for the ten days prior to 24 February 2024. 1,386,991of the Consideration Shares (being 50%) will be allotted on the 12-month anniversary of completion with1,386,991 of the Consideration Shares (being 50%) being allotted on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group at the time of the allotments. For the period ending December 31, 2024, Cryo Store Limited reported total revenue of £0.89 million and EBITDA of £0.52 million. As of December 31, 2024, Cryo Store Limited reported total common equity of £0.84 million. Geoff Nash, Camilla Hume, Harriet Ward, Nigel Birks, Louise Talbot of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Cryo Store Limited on February 27, 2025.
お知らせ • Jan 31hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million.hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million on January 29, 2025. Under the terms of agreement, the Acquisition has been completed for a cash consideration of €10.0 million, wholly funded from the Group's existing cash resources. For the period ending December 31, 2024, The Mannheim and Kiel units recorded unaudited revenues of €19.9 million, with an adjusted EBITDA loss of €1.8 million. Under hVIVO's ownership the two units will undergo an investment and restructuring programme to assist with their integration which is expected to cost c.€2.5 million in 2025 including net liabilities being acquired of less than €0.5 million. Following the Acquisition, average contract sizes across the Group are anticipated to increase, as well as growth in the CRS sales pipeline. The current senior leadership team at CRS, consisting of Dr. Elisabeth Lackner, Chief Executive Officer; Catherine Canales, Chief Commercial Officer; Prof. Dr. Thomas Forst, Chief Medical Officer; and Till Mieskes, Chief Financial Officer, will continue in their roles. The Acquisition expected to be earnings accretive in 2026. The integration of the Acquisition into the wider Group is expected to impact EBITDA margins in the short term and the Group expects to deliver strong revenue growth in 2026 and a significant improvement on EBITDA margins following the integration of CRS. Geoff Nash and Camilla Hume of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Two Clinical Research Units of Crs Clinical Research Services Management GmbH on January 29, 2025.
お知らせ • Aug 20hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024hVIVO plc announced that they will report first half, 2024 results on Sep 10, 2024
お知らせ • Aug 05hVIVO Proposes Cancellation of Admission to Trading on Euronext GrowthhVIVO plc announced its intention to cancel its admission ("the Cancellation") to trading on Euronext Growth. As hVIVO's primary operations, along with the majority of its employees and investor base, are in the UK,the Board has decided to consolidate trading of the Company's stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO's Ordinary Shares which will continue to trade on AIM under the ticker "HVO". In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024.
お知らせ • Apr 16hVIVO plc, Annual General Meeting, May 13, 2024hVIVO plc, Annual General Meeting, May 13, 2024, at 10:00 Coordinated Universal Time.
お知らせ • Mar 27hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024hVIVO plc announced that they will report fiscal year 2023 results on Apr 09, 2024
お知らせ • Feb 15hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,955,178 Price\Range: £0.28 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 02hVIVO plc Signs £6.3 Million Human Challenge Study ModelhVIVO plc announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers. The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset. Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD. To date, no antiviral has been approved in the prevention or treatment of HRV infection.
お知らせ • Sep 12hVIVO plc Increases Revenue Guidance for 2023The Board of hVIVO plc has increased its revenue guidance to £55 million for 2023.
お知らせ • Aug 24hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023hVIVO plc announced that they will report first half, 2023 results on Sep 12, 2023
お知らせ • Jun 30hVIVO plc to Develop Human Metapneumovirus Challenge ModelhVIVO plc is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in first half 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from second half of 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide. Up to 16% of the children infected with hMPV develop more severe symptoms2, with over 16,000 deaths worldwide in children under the age of five each year. Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.
お知らせ • Jan 25hVIVO plc Provides Earnings Guidance for the Full Year 2022hVIVO plc provided earnings guidance for the full year 2022. The group expected to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.
